The main molecules targeting MM cells developed to date are monoclonal antibodies (mAb), including anti-CD38 mAb [71], anti-CD138 mAb [72], anti-BCMA mAb [73] and anti-SLAMF7 mAb [74], which have been used in actual targeted therapy for MM. This evidence concerns the gene SDC1 and Miyoshi myopathy.